Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00752011 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of TAS-106 in Combo With Carboplatin

A Phase 1 study of Cancer and Solid Tumors, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
45
Enrollment target
1
Study location

NCT00752011: Completed Phase 1 study of Cancer and Solid Tumors, sponsored by M.D. Anderson Cancer Center.

NCT00752011 is a Phase 1 study of Cancer and Solid Tumors that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00752011, a Phase 1 study of Cancer and Solid Tumors, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to find the highest safe dose of the combination of TAS-106 and carboplatin that can be given to patients with advanced cancer or cancer that has spread. Objectives: Primary Objectives: To determine the maximum tolerated dose (MTD) of the combination of TAS-106 and carboplatin administered by intravenous infusion every 3 weeks. To perform Pharmacokinetic (PK) analysis of TAS-106 and carboplatin Secondary objectives: To assess the antitumor activity of TAS-106 combined with carboplatin To investigate the relationship between selected biomarkers and efficacy and safety outcomes.

Conditions Studied

Cancer Solid Tumors

Interventions

  • DRUG Carboplatin
  • DRUG TAS-106

Study Locations (1)

Texas

  • UT MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2008-06
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00752011 record still lists

NCT00752011 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Carboplatin is the first listed.

NCT00752011 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00752011 about?

NCT00752011 is a clinical study titled "Phase I Study of TAS-106 in Combo With Carboplatin". The goal of this clinical research study is to find the highest safe dose of the combination of TAS-106 and carboplatin that can be given to patients with advanced cancer or cancer that has spread. Objectives: Primary Objectives: To determine the maximum tolerated dose (MTD) of the combination of...

What is the current status of trial NCT00752011?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2008-06.

What conditions does trial NCT00752011 study?

This clinical trial studies the following conditions: Cancer, Solid Tumors.

What interventions are being tested in trial NCT00752011?

The interventions under investigation include: Carboplatin (DRUG), TAS-106 (DRUG).

Who is sponsoring clinical trial NCT00752011?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00752011 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00752011's enrollment target sits among peer trials

45 446th of 615 higher than 168 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00752011, the US trial registry maintained by the National Library of Medicine. NCT00752011 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.